# Myeloid Cells and Innate Immunity in Solid Tumors

> **NIH NIH R13** · KEYSTONE SYMPOSIA · 2020 · $5,785

## Abstract

ABSTRACT
Support is requested for a Keystone Symposia conference entitled Myeloid Cells and Innate Immunity in Solid
Tumors, organized by Drs. Judith A. Varner, Lisa M. Coussens and Dmitry I. Gabrilovich. The conference will
be held in Snowbird, Utah from September 20-24, 2020.
The field of cancer immunology is moving at a rapid pace, with discoveries based on T cell biology and T cell
targeted therapeutics eliciting real clinical successes and excitement about the future of cancer care. However,
as only twenty percent of patients respond to T cell targeted therapeutics, further work must be done to
harness the power of immunology in cancer care. Recent research has shown that myeloid cells create major
roadblocks to cancer eradication by promoting immune suppression, angiogenesis and resistance to immune
therapy. Advances in the science of these diverse cell types, roles and mechanisms governing myeloid cells in
cancer, along with the recent developments of myeloid cell targeted therapeutics, has generated significant
interest in the academic and pharmaceutical communities. Conferences that gather experts to focus discussion
exclusively on roles of myeloid cells and innate immunity in cancer will help to move our understanding of
cancer immune suppression and the field of cancer immune therapy forward. The objectives of this proposed
conference are to present the latest developments in our understanding of the origins and contributions of
various myeloid cell subsets to tumor growth and metastasis. Additionally, this conference will challenge
paradigms about macrophage and granulocyte origins in tumors, about links between metabolism and function,
and about mechanisms by which myeloid cells control immunity. The conference will also feature the latest
clinical studies of myeloid cell targeted therapeutics in cancer which will stimulate new ideas, collaborations
and advance development of new cancer immune therapeutics.

## Key facts

- **NIH application ID:** 10070815
- **Project number:** 1R13CA254451-01
- **Recipient organization:** KEYSTONE SYMPOSIA
- **Principal Investigator:** Thale Cross Jarvis
- **Activity code:** R13 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $5,785
- **Award type:** 1
- **Project period:** 2020-07-01 → 2021-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10070815

## Citation

> US National Institutes of Health, RePORTER application 10070815, Myeloid Cells and Innate Immunity in Solid Tumors (1R13CA254451-01). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10070815. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*